Janssen Pharmaceutical Co., a unit of New Brunswick, N.J.-based Johnson & Johnson, noted that the World Health Organization included Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer in the updated Essential Medicines List.